U.S. FDA Approves Trodelvy for First-Line Treatment of Metastatic Triple-Negative Breast Cancer

Дата публикации: 24-06-2026 08:06:26

FOSTER CITY, Calif.--(BUSINESS WIRE) -- June 24, 2026 -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Trodelvy (sacituzumab govitecan-hziy), a first-in-class Trop-2-directed...

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	FDA Approves Keytruda (pembrolizumab) and Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)	0	17.02	25-06-2026
2	FDA Approves Jideytro (zidesamtinib) for Previously Treated ROS1-Positive Non-Small Cell Lung Cancer	0	16.54	22-07-2026
3	FDA Accepts New Drug Application for Genentech’s Giredestrant in ER-Positive Early-Stage Breast Cancer, the First and Only Oral SERD With Positive Phase III Results in the Curative Setting	0	11.63	01-06-2026
4	FDA Approves Revtorpyk (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer	0	18.09	14-07-2026
5	U.S. FDA Grants Priority Review of New Drug Application for Gilead’s Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir	0	14.72	29-04-2026
6	FDA Approves Keytruda (pembrolizumab) and Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer	0	11.85	10-07-2026
7	U.S. FDA Approves Padcev plus Keytruda or Keytruda Qlex as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility	0	13.8	10-07-2026
8	FDA Approves Sacituzumab Govitecan-hziy as Monotherapy and in Combination with Pembrolizumab for First-Line Treatment of TNBC	0	13.99	05-08-2026
9	FDA Approves Trodelvy — A Breakthrough Treatment For One Of The Deadliest Breast Cancers	8	7	30-06-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 9. Тональность: 0. Информативность: 20.66. Источник: www.drugs.com.